You are here:

everolimus (Certican)

Advice

in the absence of a submission from the holder of the marketing authorisation:

everolimus (Certican®) is not recommended for use within NHS Scotland.

Indication under review: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: everolimus (Certican)
SMC Drug ID: 1288/17
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 November 2017

Back